Maxim analyst Jason McCarthy downgraded CNS Pharmaceuticals (CNSP) to Hold from Buy after the company reported that the primary analysis of its clinical trial evaluating Berubicin for the treatment of recurrent or progressive Glioblastoma Multiforme did not demonstrate statistically significant superiority in overall survival, the primary endpoint.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNSP:
- Biotech Alert: Searches spiking for these stocks today
- CNS Pharmaceuticals reports cash position of $14M as of February 26
- CNS Pharmaceuticals Inc trading halted, news pending
- CNS Pharmaceuticals announces 1-for-50 reverse stock split
- CNS Pharmaceuticals to present at Glioblastoma Drug Development Summit